KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Neogenomics (NEO) over the last 17 years, with Q3 2025 value amounting to 14.38%.

  • Neogenomics' EBITDA Margin fell 17500.0% to 14.38% in Q3 2025 from the same period last year, while for Sep 2025 it was 17.04%, marking a year-over-year decrease of 27200.0%. This contributed to the annual value of 13.94% for FY2024, which is 42700.0% up from last year.
  • Latest data reveals that Neogenomics reported EBITDA Margin of 14.38% as of Q3 2025, which was down 17500.0% from 26.27% recorded in Q2 2025.
  • Neogenomics' EBITDA Margin's 5-year high stood at 10.7% during Q4 2024, with a 5-year trough of 44.4% in Q1 2022.
  • For the 5-year period, Neogenomics' EBITDA Margin averaged around 21.59%, with its median value being 19.02% (2022).
  • Its EBITDA Margin has fluctuated over the past 5 years, first plummeted by -374600bps in 2021, then skyrocketed by 188400bps in 2023.
  • Quarter analysis of 5 years shows Neogenomics' EBITDA Margin stood at 33.06% in 2021, then skyrocketed by 42bps to 19.02% in 2022, then surged by 37bps to 11.94% in 2023, then increased by 10bps to 10.7% in 2024, then tumbled by -34bps to 14.38% in 2025.
  • Its EBITDA Margin stands at 14.38% for Q3 2025, versus 26.27% for Q2 2025 and 16.56% for Q1 2025.